Who is sponsoring NCT02137096?

NCT02137096 is sponsored by University of Florida.

What drugs are being tested in NCT02137096?

Interventions in NCT02137096: Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation.

What condition does NCT02137096 study?

NCT02137096 studies Recurrent Nasopharynx Carcinoma.

Is NCT02137096 still recruiting?

NCT02137096 is currently terminated. Last updated 29 May 2019.

Are results published for NCT02137096?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-05-29 · How we verify

NCT02137096

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Terminated Phase 3 Results posted Last updated 29 May 2019

What this trial tests

Phase 3 trial testing Etoposide phosphate in Recurrent Nasopharynx Carcinoma in 1 participant. Terminated before completion.

Timeline

1 June 2014

Primary endpoint
9 May 2017

9 May 2017

Quick facts

Lead sponsor	University of Florida
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	1 June 2014
Primary completion	9 May 2017
Estimated completion	9 May 2017
Sites	1 location across United States

Drugs / interventions tested

Etoposide phosphate — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Ifosfamide (IFOSFAMIDE) — full drug profile →
Autologous Stem Cell Transplantation — full drug profile →

Conditions studied

Recurrent Nasopharynx Carcinoma — all drugs for Recurrent Nasopharynx Carcinoma →

Sponsor

University of Florida

Who can join

Adults 2 to 30, any sex, with Recurrent Nasopharynx Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluate the Tumor Response
Time frame: 12 months after completion of treatment
To evaluate the response rates for patients undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults.

Sponsor's own description

This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Etoposide phosphate

Trials testing the same drug.

NCT02106988 — Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma · Phase 2 · active not recruiting
NCT02130869 — A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous · Phase 1 · completed
NCT01969435 — Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autol · Phase 2 · completed

Other recruiting trials for Recurrent Nasopharynx Carcinoma

Currently open trials in the same condition.

NCT07332247 — PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NP · Phase 2 · recruiting
NCT03074513 — Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · Phase 2 · active not recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02137096 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 29 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02137096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing